Risks

Elevated leverage and negative interest coverage increase refinancing sensitivity versus equity-light peers, but ARE’s long-duration lease model and asset quality support access to capital markets.

Near-term liquidity is thin relative to office and industrial REIT peers, so higher rates or tighter credit conditions could constrain growth funding and dividend flexibility.

Tenant demand remains exposed to life-science funding cycles, and slower biotech capital formation could delay leasing and rent growth versus more diversified lab landlords.

Development and lease-up timing risk can pressure cash flow conversion versus stabilized peers, because new supply must be absorbed before full NOI contribution is realized.

Portfolio concentration in innovation clusters creates local market dependence, so a regional slowdown could affect occupancy and mark-to-market rents more than broader diversified REITs.

Opportunities

ARE’s leading life-science platform positions it to capture a rebound in biotech R&D spending, which should translate into leasing demand ahead of smaller lab landlords.

High barriers to entry in core innovation hubs support pricing power versus generic office REITs, enabling better rent retention when demand normalizes.

Scarcity of purpose-built lab space in top markets can favor ARE’s scale and pipeline, allowing it to absorb demand faster than fragmented peers.

Long lease durations and specialized tenant relationships improve visibility versus cyclical property owners, supporting steadier occupancy and cash flow through market volatility.

If capital markets reopen for biotech, ARE is well placed to benefit from expansion demand because its existing cluster presence lowers tenant relocation friction versus peers.

Overall Score

ARE’s dominant life-science positioning and scarcity-driven pricing power create strong upside, while leverage, liquidity, and biotech-cycle exposure remain the main constraints versus peers.